Issue 23

PSYCH VIRTUAL INVESTOR SUMMIT: EUROPE AND ASIA

We’re less than two weeks away from our first PSYCH Virtual Investor Summit: Europe & Asia. Join us on 21st April to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help develop this emerging frontier.

Featured speakers include Ronan Levy, Co-Founder & Executive Chairman, Field Trip Health Ltd.; Peter Reitano, Chief Executive Officer, Gwella; and keynote speaker, Professor David Nutt, Director of Neuropsychopharmacology, Imperial College London and Head of Research, Awakn Life Sciences.

The summit will showcase expanding businesses looking for capital, provide AI-powered digital networking opportunities and deliver a concise programme highlighting the latest business developments, industry insights and psychedelic research efforts around the globe.

Event runs between 12:00 – 18:00 BST / 07:00 – 13:00 EST. Hope to see you there

Register for free tickets

BUSINESS AND INVESTMENT

Entheon launches DNA test to better inform psychedelic-assisted psychotherapy.

Core One announces acquisition of US-based ketamine therapy clinics.

MINDCURE files patent for digital platform to enhance effectiveness of psychedelic-assisted therapies.

Psilocybin distribution centres to open in Oregon.

Tryp Therapeutics announces OTCQB listing and DTC eligibility.

Exploring the potential to create ethical psychedelics companies.

Tryp Therapeutics appoints Greg McKee as Chief Executive Officer.

Wesana Health announces closing of C$16.1 million investment.

Silo Wellness hires marketing and cannabis industry veterans for Marley psychedelics brand.

PsyBio appoints Dr Michael Spigarelli as Chief Medical Officer.

RESEARCH AND SCIENCE

Australian researchers conducting study on managing meth addiction using psilocybin.

Exploring Ibogaine, one of the most promising and perilous psychedelic drug treatments.

University of California launches US$6.4 million psychedelics research programme.

Non-profit teams up with leading psychedelic research centre to conduct psilocybin study.

MindMed announces new data which may maximise therapeutic effects of MDMA dosing.

Nova and FourthWall Testing establishing a serotonin research centre.

Therapists in Denver using psychedelic therapy to treat mental health conditions.

REGULATION AND LEGISLATION

Third Massachusetts city approves psychedelics decriminalisation measure.

California senators approve bill to legalise possession of various psychedelics.

Partner with us